Helius Med Technologies Inc Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq:HSDT) has announced participation in several virtual investor conferences during January 2021. Key events include:

• The Demy-Colton Digital Medicine and Medtech Showcase from January 11-15, with on-demand access starting January 6th.
• The H.C. Wainwright BioConnect Conference from January 11-14, with presentations available on January 11th.
• The Sidoti Winter 2021 Conference on January 13-14, where management will present on January 13th.
• The ICR Conference from January 11-14, with management presenting on January 14th.

Helius Medical Technologies (HSDT) announced a 1-for-35 reverse stock split effective December 31, 2020, aimed at complying with Nasdaq listing requirements. Consequently, the outstanding shares will decrease from approximately 51.9 million to 1.5 million, while the number of authorized shares remains at 150 million. The common stock will trade on a split-adjusted basis starting January 4, 2021. Shareholders will receive cash for any fractional shares. More details can be found in the definitive proxy statement filed with the SEC.

Helius Medical Technologies (HSDT) reported its Q3 2020 financial results. Revenue was $131K, down from $150K in Q3 2019. Operating loss decreased to $3.7M from $5.7M year-over-year. The company closed a $3.4M private placement to support operations into Q1 2021. Following a leadership change, Helius continues to pursue FDA clearance for its Portable Neuromodulation Stimulator (PoNS) device to treat Multiple Sclerosis symptoms. Authorized clinics for PoNS treatment increased from 7 to 27 in Canada amid ongoing challenges from the COVID-19 pandemic.

Helius Medical Technologies (NASDAQ:HSDT) will present at the virtual Fall Investor Summit from November 16-18, 2020. This summit aims to connect smallcap and microcap companies with over 300 investors.

Helius focuses on developing non-invasive neurotech solutions, particularly the Portable Neuromodulation Stimulator (PoNS™). Currently authorized for sale in Canada, the PoNS™ is aimed at treating gait deficits associated with multiple sclerosis and mild traumatic brain injury. The device is under FDA review for potential use in the U.S.

Helius Medical Technologies (HSDT) announced its participation in several upcoming investor conferences. Management will present at the Investor Summit Group’s Virtual Fall Summit on November 17 at 1:00 p.m. ET. Additionally, they will engage in virtual 1x1 meetings at the Alliance Global Partners’ Virtual Healthcare Symposium on November 19, with no formal presentation. Furthermore, they will present at the Sidoti & Co. Virtual Fall Microcap Conference on the same day at 9:15 a.m. ET. Live webcasts will be available on Helius’s investor relations website.

Helius Medical Technologies has announced the expansion of its clinic network to 27 locations across Canada, enhancing access to PoNS Treatment for individuals with gait and balance deficits due to multiple sclerosis and traumatic brain injury. The initiative targets established neurorehabilitation providers in Ontario with existing referral networks. Helius aims for further clinic authorizations to support PoNS Treatment accessibility as it recovers from pandemic impacts. The PoNS device is currently under regulatory review in the U.S., EU, and Australia.

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced that it will release its third quarter fiscal year 2020 financial results on November 12, 2020, after market close. A conference call is scheduled for 5:45 p.m. ET the same day to discuss these results. Interested parties can join the call or access a live webcast via the company’s investor relations website. Helius focuses on developing non-invasive neurotechnology aimed at enhancing neurological wellness, with its leading product, the Portable Neuromodulation Stimulator (PoNS™), currently authorized for sale in Canada but still investigational in other markets.

Helius Medical Technologies (Nasdaq:HSDT) has successfully closed a private placement raising approximately $3.4 million through the sale of 6,567,868 Class A Common Stock shares and warrants. Each unit was sold at $0.52, with warrants exercisable at $0.452 per share for three years. Notably, affiliates of Helius' CEO and CFO participated under the same terms. The funds will support operations and general corporate purposes. These securities are subject to resale restrictions and the company will file a registration statement with the SEC for their resale.

Helius Medical Technologies (Nasdaq:HSDT) announced a private placement agreement to sell 6,664,022 shares of Class A Common Stock and warrants to purchase 3,332,013 shares at $0.52 per unit, totaling approximately $3.4 million. The closing is anticipated around October 23, 2020, pending customary conditions. Proceeds will fund operations and general corporate purposes. The placement includes related-party transactions but adheres to TSX exemptions, with the company intending to file a resale registration statement with the SEC. The PoNS™ device is under regulatory review in multiple regions.